Palliative care programs were challenging during the COVID-19 pandemic.
Allegheny Health Network
Latest Content
Dr. Homa suggests many women consider freezing their eggs during their childbearing years.
A multi-disciplinary approach could help better manage obesity following bariatric surgery.
Dr. Bailey highlights the innovative nature of the procedure and breaks down the process at his institution.
Dr. Bajona highlights the patient risks of HCM, new advances in treatment options, and the importance of screening efforts.
Dr. Lee highlights the process of identifying CTEPH and the patient population, as well as the available treatments for the condition.
Smoking and alcohol use are known risk factors that could impact fertility.
The goal of the Olivia's Angels is to create a culture of perinatal loss care throughout the system.
AHN is one of the few hospitals who have implemented this type of program to treat IBD complications.
Dr. Poornima explores improving engagement in women’s cardiovascular care from both a provider and a patient level.
Cardiovascular disease is the leading cause of death for women.
Dr. Radhakrishnan discusses both the effects of gender bias and why women don't get screened for heart disease.
On Wear Red Day, Dr. Ivanova advocates for increased awareness and diversity in women's cardiovascular care.
February 3 is National Women's Physician Day.
A pediatrician discusses the stakes at hand for children whose parents are considering available vaccines now.
A look into how Allegheny Health Network prioritizes the valuable therapy amid rising cases.
A look into how Allegheny Health Network launched its multi-specialty referral system for post-hospitalized COVID-19 patients.
NYU Langone is developing a comprehensive care program that includes psychiatric evaluations during postpartum OBGYN care.
Jefferson and West Penn join just 130 hospitals nationwide to receive the honor from the ACC, and AGH is the only facility in the region with a maximum three-star rating across four surgical categories
Patients at AHN’s Autoimmunity Institute participated in international clinical trial testing of Saphnelo™ (anifrolumab) – the first new biologic agent in more than a decade for the treatment of adult patients with moderate to severe lupus.
With Only 21 Facilities Achieving this Award Nationally, AGH Ranks Among the Most Elite Mitral Valve Programs in the Country